You are in the accessibility menu

Please use this identifier to cite or link to this item: http://acervodigital.unesp.br/handle/11449/117725
Title: 
Hepatitis C virus molecular evolution: Transmission, disease progression and antiviral therapy
Author(s): 
Institution: 
  • Hosp Ninos Dr Ricardo Gutierrez
  • Inst Diagnost & Referencia Epidemiol
  • Universidade Estadual Paulista (UNESP)
  • Univ Nacl Autonoma Mexico
ISSN: 
1007-9327
Sponsorship: 
  • project Salud
  • CONACYT
  • PAPIIT
  • Direccion General de Asuntos del Personal Academico, Universidad Nacional Autonoma de Mexico
  • Argentine National Agency for Scientific and Technology Promotion (PICT)
  • National Research Council (CONICET, PIP)
Sponsorship Process Number: 
  • project Salud2012-C01-181585
  • PAPIITTA200112
  • Argentine National Agency for Scientific and Technology Promotion (PICT)804
  • National Research Council (CONICET, PIP)51
Abstract: 
Hepatitis C virus (HCV) infection represents an important public health problem worldwide. Reduction of HCV morbidity and mortality is a current challenge owned to several viral and host factors. Virus molecular evolution plays an important role in HCV transmission, disease progression and therapy outcome. The high degree of genetic heterogeneity characteristic of HCV is a key element for the rapid adaptation of the intrahost viral population to different selection pressures (e.g., host immune responses and antiviral therapy). HCV molecular evolution is shaped by different mechanisms including a high mutation rate, genetic bottlenecks, genetic drift, recombination, temporal variations and compartmentalization. These evolutionary processes constantly rearrange the composition of the HCV intrahost population in a staging manner. Remarkable advances in the understanding of the molecular mechanism controlling HCV replication have facilitated the development of a plethora of direct-acting antiviral agents against HCV. As a result, superior sustained viral responses have been attained. The rapidly evolving field of anti-HCV therapy is expected to broad its landscape even further with newer, more potent antivirals, bringing us one step closer to the interferon-free era. (C) 2014 Baishideng Publishing Group Inc. All rights reserved.
Issue Date: 
21-Nov-2014
Citation: 
World Journal Of Gastroenterology. Pleasanton: Baishideng Publishing Group Inc, v. 20, n. 43, p. 15992-16013, 2014.
Time Duration: 
15992-16013
Publisher: 
Baishideng Publishing Group Inc
Keywords: 
  • Hepatitis C virus
  • Evolution
  • Phylogenetics
  • Drug resistance
  • Clinical outcome
Source: 
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4239486/
URI: 
Access Rights: 
Acesso restrito
Type: 
outro
Source:
http://repositorio.unesp.br/handle/11449/117725
Appears in Collections:Artigos, TCCs, Teses e Dissertações da Unesp

There are no files associated with this item.
 

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.